US 12,144,827 B2
ROR1 targeting chimeric antigen receptor
Spencer Park, Seattle, WA (US); Queenie Vong, South San Francisco, CA (US); Blythe Sather, South San Francisco, CA (US); Byoung Ryu, South San Francisco, CA (US); Marc Lajoie, South San Francisco, CA (US); Howell Moffett, South San Francisco, CA (US); Brian Weitzner, South San Francisco, CA (US); Yun Song, South San Francisco, CA (US); Scott Boyken, South San Francisco, CA (US); Neeraj Sharma, South San Francisco, CA (US); Shobha Potluri, South San Francisco, CA (US); and Bijan Boldajipour, South San Francisco, CA (US)
Assigned to Lyell Immunopharma, Inc., South San Francisco, CA (US)
Filed by Lyell Immunopharma, Inc., South San Francisco, CA (US)
Filed on Feb. 24, 2022, as Appl. No. 17/680,024.
Claims priority of provisional application 63/309,393, filed on Feb. 11, 2022.
Claims priority of provisional application 63/263,229, filed on Oct. 28, 2021.
Claims priority of provisional application 63/153,878, filed on Feb. 25, 2021.
Prior Publication US 2023/0022654 A1, Jan. 26, 2023
Int. Cl. A61K 35/17 (2015.01); A61P 35/00 (2006.01); C07K 14/71 (2006.01); C07K 16/40 (2006.01); C12N 15/62 (2006.01)
CPC A61K 35/17 (2013.01) [A61P 35/00 (2018.01); C07K 14/71 (2013.01); C07K 16/40 (2013.01); C12N 15/62 (2013.01); C07K 2317/565 (2013.01)] 20 Claims
 
1. A polynucleotide encoding a chimeric polypeptide which comprises the amino acid sequence set forth in SEQ ID NO: 57.
 
2. A polynucleotide comprising the nucleotide sequence set forth in SEQ ID NO: 5.8.
 
3. A polynucleotide comprising the nucleotide sequence set forth at 426 to 4,022 of the nucleotide sequence set forth in SEQ ID NO: 58.